U.S., July 28 -- ClinicalTrials.gov registry received information related to the study (NCT07727889) titled 'A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa' on July 22.
Brief Summary: Hidradenitis suppurativa is a chronic, recurrent inflammatory skin disease characterized by painful inflammatory nodules, abscesses, draining tunnels, and scarring. Patients with moderate-to-severe disease may experience inadequate responses, intolerance, or loss of response to conventional systemic therapies and biologic agents.
This prospective, open-label, single-arm, real-world study will evaluate the effectiveness, safety, patient-reported outcomes, and treatment persistence of upadacitinib in 50 adults with mo...